That puts the research-based sector in a difficult spot. Will it pay, in explicit savings drawn from the existing pool of funded medicines and technologies, for the privilege of faster, allegedly lighter-touch assessment pathways for a handful of new 'unicorn' therapies? Is it worth it? …
If the demand is to pay for reform, are these reforms really worth paying for?
May 18, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Injunction blocks generic launch of key HIV combination medicine
August 6, 2026 - - Latest News -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
NSW urged to think pharmacy first as 250 pharmacists near completion of advanced training
August 6, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
The complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Pharmac announces plan to revise its recently expanded patient advisory function
August 4, 2026 - - Latest News